|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Since the shortcomings of tumor tissue detection are well known, the liquid biopsy is more appropriate to track T790M status.
|
31805270 |
2020 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Plasma T790M detection was associated with a larger median baseline tumor size (56 mm for T790M-positive vs 39 mm for T790M-negative; P < .0001) and the presence of extrathoracic disease (58% for M1b-positive vs 39% for M0-1a-positive; P = .002).
|
31769875 |
2020 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Multiplex genomic testing of pretreatment tumor tissue may thus provide a means of identifying patients likely to develop T790M-mediated TKI resistance and therefore inform treatment selection.
|
31710890 |
2020 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
DNAs from pretreatment tumor biopsy samples and re-biopsy samples were assessed to detect T790M by the Cobas EGFR Mutation Test v2 (Cobas) and for quantitating T790M by droplet digital polymerase chain reaction (ddPCR).
|
31751804 |
2020 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Clinical Features of Patients with an Epidermal Growth Factor Receptor T790M Mutation Detected in Circulating Tumor DNA.
|
31494653 |
2020 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Ultra-sensitive detection of tumor T790M mutation concerned 8% of EGFR-mutated TKI-naïve NSCLC patients and has a negative prognostic value only for T790M VAF over 1%.
|
31841714 |
2020 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this clinical scenario, the tumor may respond transiently to reversible first-generation EGFR inhibitors (gefitinib or erlotinib), but evolving mechanisms of on-target resistance-in clinical specimens and preclinical systems-indicate that EGFR C797S along with EGFR T790M can evolve.
|
31377341 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Osimertinib has favorable efficacy in patients with NSCLC harboring T790M, detected from ctDNA with unknown tumor mutation status, in whom disease had progressed during prior EGFR-TKI therapy.
|
30189719 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Standard treatment for cases of non-small cell lung cancer (NSCLC) exhibiting acquired drug resistance includes tumor rebiopsy, epidermal growth factor receptor (<i>EGFR</i>) mutation testing (e.g., for T790M mutations), and the subsequent administration of third-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs).
|
31124335 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Circulating Tumor DNA T790M Testing as a Predictor of Osimertinib Efficacy in Epidermal Growth Factor Receptor Mutant Non-small Cell Lung Cancer: A Single Center Experience.
|
31280508 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Baseline T790M occurred in 17% of the tumors.
|
31737495 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We hypothesized that treatment with cabozantinib plus erlotinib in <i>EGFR</i> mutation-positive NSCLC following progression on EGFR TKI therapy may allow tumors to overcome this resistance or restore sensitivity to therapy regardless of T790M status.
|
30915273 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Third-generation TKIs are able to block tumor growth through an irreversible binding to the T790M-mutated receptor.
|
31644442 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The third-generation EGFR TKI, osimertinib has been approved for patients whose tumor has become resistant through the secondary T790M resistant EGFR mutation.
|
31411906 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
A tag-based next generation sequencing (NGS) platform capable of tagging rare circulating tumor DNA alleles was employed in this study for the identification of T790M mutation in 42 post-TKI NSCLC patients.
|
31029076 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Eligible patients were aged 20 years or older and had advanced NSCLC harbouring an activating EGFR mutation and progressing after first-generation or second-generation EGFR TKI treatment, a defined tumour T790M mutation status, an Eastern Cooperative Oncology Group performance status of 0-1, at least one measurable extracranial lesion, defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and adequate organ function.
|
31587882 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
[<sup>18</sup> F]FEWZ is the first evidence of a radiolabeled third generation anilinopyrimidine-derived tyrosine kinase inhibitor targeting T790M mutation bearing tumours in vivo.
|
31132309 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The ddPCR assay is an ultra-sensitive method to detect a minor amount of de novo T790M mutations in tumor samples.
|
30760406 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Real-time PCR analysis showed that the right-sided tumor had an epidermal growth factor receptor (EGFR) mutation presenting as point mutation T790M in exon 20, while the left-sided tumor had a point mutation L858R in exon 21 of EGFR.
|
31426797 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Mutation profiling of tumour DNA in cerebrospinal fluid (CSF) samples can be used to determine the presence of the <i>EGFR</i> T790M resistance mutation, indicating that osimertinib, a CNS-penetrating 3<sup>rd</sup> generation TKI may be efficacious.
|
31285867 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
T790M was detected in the tumor samples of 23 patients, the blood samples of two patients, and both the tumor and blood samples of five patients.
|
30920616 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Ganetespib also inhibited in vivo tumor growth in resistant cells harboring EGFR T790M.
|
30952716 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Disruption of mTORC2 inhibited EGFR/T790M-positive tumor growth in mouse brain and prolonged animal survival correlating a diminished tumor angiogenesis and recruitment of IBA1+ microglia/macrophages in tumor microenvironment.
|
30796032 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
It is approved for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, and for patients with T790M-positive advanced NSCLC whose disease has progressed on or after EGFR-TKI therapy.
|
30875094 |
2019 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
T790M coexisted with L858R mutation (8/11) more than with deletions in exon 19 (19del) mutation (3/11) in TKI-naive tumors, while 19del co-occurred as often as L858R in post-TKI tumors.
|
31463130 |
2019 |